First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 921-929

  Bergh, Jonas ^a,b   Bondarenko, Igor M ^c   Lichinitser, Mikhail R ^e   Liljegren, Annelie ^a   Greil, Richard ^g   Voytko, Nataliya L ^d   Makhson, Anatoly N ^f   Cortes, Javier ^h   Lortholary, Alain ⁱ   Bischoff, Joachim ^k   Chan, Arlene ^l   Delaloge, Suzette ^j   Huang, Xin ^m   Kern, Kenneth A ^m   Giorgetti, Carla ^m  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Dnipropetrovsk City Multiple Discipline Clinical Hospital No 4   (Ukraine)

^d Kyiv City Oncologic Hospital   (Ukraine)

^e Center for Cancer Prevention and Screenin   (Russian Federation)

^f City Oncology Clinical Hospital No 62   (Russian Federation)

^g PARACELSUS MEDICAL UNIVERSITY   (Austria)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ Centre Catherine de Sienne   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k OTTO VON GUERICKE UNIVERSITY   (Germany)

^l Mount Medical Centre   (Australia)

^m PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TAXOID;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; APPETITE DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; COHORT ANALYSIS; COLLAPSE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; FACE EDEMA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HAZARD RATIO; HEADACHE; HEART ARREST; HEART FAILURE; HUMAN; HUMAN TISSUE; HYPERTENSION; LACRIMATION DISORDER; LEUKOPENIA; LIMB PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMOTHORAX; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SHOCK; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INTERNATIONAL COOPERATION; LUNG CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; INDOLES; INTERNATIONAL AGENCIES; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RECEPTOR, ERBB-2; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84860625265     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.7376     Document Type: Article

References (30)

1. sanofi-aventis US: Taxotere (docetaxel) injection concentrate prescribing information, 2010. http:// products.sanofi-aventis.us/Taxotere/taxotere.html
2. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003 (Pubitemid 36109749)
3. Banerjee S, Dowsett M, Ashworth A, et al: Mechanisms of disease: Angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4:536-550, 2007 (Pubitemid 47351464)
4. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
5. Paulsson J, Sjöblom T, Micke P, et al: Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175:334-341, 2009
6. Tsuda H, Morita D, Kimura M, et al: Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 96:48-53, 2005 (Pubitemid 40310025)
7. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003 (Pubitemid 38019277)
8. Goswami S, Sahai E, Wyckoff JB, et al: Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65:5278-5283, 2005 (Pubitemid 40827339)
9. Abrams TJ, Murray LJ, Pesenti E, et al: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021, 2003
10. Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
11. Mariani G, Cardoso F, Besse-Hammer T, et al: Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): An exploratory evaluation. J Clin Oncol 26: 630s, 2008 (suppl 15S; abstr 14534)
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
13. Pfizer: Sutent (sunitinib malate) prescribing information, 2011. http://www.pfizer.com/files/products/ uspi-sutent.pdf
14. Robert NJ, Saleh MN, Paul D, et al: Sunitinib plus paclitaxel versus bevacizumab plus docetaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 11:82-92, 2011
15. Crown J, Dieras V, Staroslawska E, et al: Phase 3 trial of sunitinib in combination with capecitabine vs capecitabine in previously treated advanced breast cancer. J Clin Oncol 28:116s, 2010 (suppl 18s; abstr LBA1011)
16. Barrios CH, Liu M-C, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
17. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584- 3590, 2009
18. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
19. Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
20. Loges S, Mazzone M, Hohensinner P, et al: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15:167-170, 2009
21. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for meta-static breast cancer. N Engl J Med 357:2666-2676, 2007
22. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
23. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239- 3247, 2010
24. Miller KD, Chap LI, Homes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
25. O'Shaughnessy J, Miles D, Gray RJ, et al: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with meta-static breast cancer (MBC). J Clin Oncol 28:115s, 2010 (suppl 15s; abstr 1005)
26. US Food and Drug Administration: FDA core presentation, Avastin (bevacizumab), for the July 20, 2010 Meeting of the Oncologic Drugs Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugs AdvisoryCommittee/UCM219978.pdf
27. Harvey V, Mouridsen H, Semiglazov V, et al: Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970, 2006 (Pubitemid 46631397)
28. Bergh J: Quo vadis with targeted drugs in the 21st century? J Clin Oncol 27:2-5, 2009
29. Lindström L, Howell S, Âström G, et al: Controversies in the management of metastatic breast cancer: Biologic evaluation of breast cancer - Should metastases be biopsied? Am Soc Clin Oncol Ed Book e7-e12, 2010
30. Lindström LS, Giorgetti C, Smeds J, et al: Ways to understand mechanism of action for targeted drugs? Gene expression analyses from paired biopsies in patients with advanced breast cancer in a substudy from the randomized study docetaxel +/- sunitinib A6181064. 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr P6-12-05)